If you or an older parent has thinning bones, chances are a small weekly pill is already sitting in the medicine cabinet. Osteoporosis treatment is a quiet routine for millions of adults past 60. Researchers are now asking whether the same pills do something else for the body.
A large analysis of 121,492 older adults in Hong Kong was published in Alzheimer's & Dementia. It found that people on the most common class of osteoporosis drugs had a 24 percent lower risk of Alzheimer's disease and related dementias than those on other bone medications.
The study tracked patients aged 60 and older from 2005 to 2021. Everyone in the analysis had osteoporosis or a fragility fracture.
The research team, based at the University of Hong Kong's LKS Faculty of Medicine, compared outcomes in people who took different types of bone drugs with those who took none.
Also read: People who live past 100 have something unusual in their gut, study finds
What these drugs are
The class is called nitrogen-containing bisphosphonates. Most readers in the United States will know them by brand names such as Fosamax (alendronate) or Reclast (zoledronate). They slow bone loss and lower the chance of a fracture.
Compared with patients who took no osteoporosis drug at all, nitrogen-containing bisphosphonate users had a 16 percent lower risk of Alzheimer's and related dementias. The signal was strongest in women and in people with a previous hip fracture.
The researchers estimated that treating 48 patients for five years could potentially prevent one case of dementia.
A possible bone and brain link
What might explain the pattern? Professor Cheung Ching-lung of the University of Hong Kong led the work. He told Fox News Digital that "Emerging evidence points to a bone-brain axis, suggesting a close link between bone and brain health."
Also read: Night sweats aren't always harmless: Seven possible medical causes
In their paper, the authors floated several biological ideas.
The drugs may dampen neuroinflammation and oxidative stress, two processes thought to drive the slow damage behind Alzheimer's. They also block an enzyme in a cell pathway called mevalonate, which has been tied to Alzheimer's pathology.
Not a reason to start the drug for brain health
This is not a signal to run to the doctor for a new prescription. The study was observational. It can show a pattern, but it cannot prove the drugs caused the lower risk.
People who stick with any medication long term tend to be healthier in other ways, which can bias this kind of result.
Also read: When is it safe to go back to work after the flu? CDC reveals new rules
The authors also noted that they lacked baseline cognitive scores, data on supplement use, and information on lifestyle factors like education and social isolation.
Rebecca M. Edelmayer is Vice President of Scientific Engagement at the Alzheimer's Association in Chicago. She told Fox News Digital that "The research points to an association, not proof that bisphosphonates protect the brain."
The analysis also looked only at patients in Hong Kong. Whether the same signal would appear in American or European populations is still an open question.
For now, anyone already taking a nitrogen-containing bisphosphonate for bone health has no reason to stop based on this study. Anyone weighing whether to start the drug should discuss bone risk and other side effects with their doctor, who can factor in the full medical picture.
Also read: 112 pregnant women infected with measles: Here's what happened to their babies
Also read: Five children have died from flu this season: Here's what you should know
This article is made and published by Mie Hermansen, who may have used AI in the preparation.
